Pharmaceutical Preparations Companies
FilingsAtlas covers 403 publicly traded US companies in the Pharmaceutical Preparations industry (SEC SIC code 2834). Together they are worth about $3.84T in market value; the largest are ELI LILLY (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV). By revenue, the biggest is Johnson & Johnson with $94.19B in fiscal 2025. 60 of the 403 companies with a reported fiscal year were profitable.
| # | Company | Ticker | Market Cap | Revenue (latest FY) | Net Income | Revenue YoY | P/E |
|---|---|---|---|---|---|---|---|
| 1 | ELI LILLY & Co | LLY | $1.04T | $65.18B FY2025 | $20.64B | +44.7% | 50.8 |
| 2 | Johnson & Johnson | JNJ | $606.63B | $94.19B FY2025 | $26.80B | +6.0% | 22.5 |
| 3 | AbbVie Inc. | ABBV | $485.89B | $61.16B FY2025 | $4.23B | +8.6% | 116.3 |
| 4 | Merck & Co., Inc. | MRK | $350.69B | $65.01B FY2025 | $18.25B | +1.3% | 19.5 |
| 5 | Abbott Laboratories | ABT | $178.85B | $44.33B FY2025 | $6.52B | +5.7% | 27.6 |
| 6 | Pfizer Inc | PFE | $161.68B | $62.58B FY2025 | $7.77B | -1.7% | 20.9 |
| 7 | Vertex Pharmaceuticals Inc / Ma | VRTX | $123.83B | $12.00B FY2025 | $3.95B | +8.9% | 31.7 |
| 8 | Bristol Myers Squibb Co | BMY | $116.06B | $48.19B FY2025 | $7.05B | -0.2% | 16.4 |
| 9 | Regeneron Pharmaceuticals, Inc. | REGN | $79.83B | $14.34B FY2025 | $4.50B | +1.0% | 18.2 |
| 10 | Teva Pharmaceutical Industries LTD | TEVA | $48.06B | $17.26B FY2025 | $1.41B | +4.3% | 34.1 |
| 11 | BeOne Medicines Ltd. | ONC | $40.42B | $5.34B FY2025 | $286.9M | +40.2% | 141.3 |
| 12 | Royalty Pharma plc | RPRX | $31.50B | $2.38B FY2025 | $770.9M | +5.1% | 31.8 |
| 13 | Zoetis Inc. | ZTS | $31.04B | $9.47B FY2025 | $2.67B | +2.3% | 12.3 |
| 14 | Alnylam Pharmaceuticals, Inc. | ALNY | $30.95B | $3.71B FY2025 | $313.7M | +65.2% | 96.1 |
| 15 | UNITED THERAPEUTICS Corp | UTHR | $24.89B | $3.18B FY2025 | $1.33B | +10.6% | 19.5 |
| 16 | Roivant Sciences Ltd. | ROIV | $24.04B | $8.3M FY2026 | -$299.8M | -71.6% | — |
| 17 | INSMED Inc | INSM | $21.04B | $606.4M FY2025 | -$1.28B | +66.7% | — |
| 18 | Viatris Inc | VTRS | $20.07B | $14.30B FY2025 | -$3.51B | -3.0% | — |
| 19 | Jazz Pharmaceuticals plc | JAZZ | $14.60B | $4.27B FY2025 | -$356.1M | +4.9% | — |
| 20 | Corcept Therapeutics Inc | CORT | $13.95B | $761.4M FY2025 | $99.7M | +12.8% | 143.7 |
| 21 | Madrigal Pharmaceuticals, Inc. | MDGL | $13.18B | $958.4M FY2025 | -$288.3M | +432.1% | — |
| 22 | BridgeBio Pharma, Inc. | BBIO | $12.39B | $502.1M FY2025 | -$724.9M | +126.3% | — |
| 23 | Summit Therapeutics Inc. | SMMT | $12.08B | $0 FY2025 | -$1.08B | — | — |
| 24 | Elanco Animal Health Inc | ELAN | $11.34B | $4.71B FY2025 | -$232.0M | +6.2% | — |
| 25 | Biomarin Pharmaceutical Inc | BMRN | $10.58B | $3.22B FY2025 | $348.9M | +12.9% | 30.2 |
| 26 | Protagonist Therapeutics, Inc | PTGX | $9.83B | $46.0M FY2025 | -$130.1M | -89.4% | — |
| 27 | TG Therapeutics, Inc. | TGTX | $8.55B | $616.3M FY2025 | $447.2M | +87.3% | 19.6 |
| 28 | Arrowhead Pharmaceuticals, Inc. | ARWR | $8.33B | $829.4M FY2025 | -$1.6M | — | — |
| 29 | Cytokinetics Inc | CYTK | $8.14B | $88.0M FY2025 | -$785.0M | +376.6% | — |
| 30 | Axsome Therapeutics, Inc. | AXSM | $8.10B | $638.5M FY2025 | -$183.2M | +65.5% | — |
| 31 | Praxis Precision Medicines, Inc. | PRAX | $7.09B | $0 FY2025 | -$303.3M | -100.0% | — |
| 32 | Ionis Pharmaceuticals Inc | IONS | $7.01B | $943.7M FY2025 | -$381.4M | +33.8% | — |
| 33 | Alkermes plc. | ALKS | $6.89B | $1.48B FY2025 | $241.7M | -5.2% | 27.8 |
| 34 | Spyre Therapeutics, Inc. | SYRE | $6.82B | $0 FY2025 | -$155.2M | — | — |
| 35 | Ligand Pharmaceuticals Inc | LGND | $6.63B | $268.1M FY2025 | $124.5M | +60.4% | 49.5 |
| 36 | Kiniksa Pharmaceuticals International, plc | KNSA | $6.55B | $677.6M FY2025 | $59.0M | +60.1% | 104.7 |
| 37 | Amneal Pharmaceuticals, Inc. | AMRX | $6.42B | $3.02B FY2025 | $72.1M | +8.1% | 89.0 |
| 38 | Rhythm Pharmaceuticals, Inc. | RYTM | $5.94B | $189.8M FY2025 | -$196.5M | +45.8% | — |
| 39 | PTC Therapeutics, Inc. | PTCT | $5.51B | $1.73B FY2025 | $682.6M | +114.5% | 7.7 |
| 40 | Mirum Pharmaceuticals, Inc. | MIRM | $5.05B | $521.3M FY2025 | -$23.4M | +54.7% | — |
| 41 | Oruka Therapeutics, Inc. | ORKA | $4.92B | $0 FY2025 | -$105.4M | — | — |
| 42 | Travere Therapeutics, Inc. | TVTX | $4.84B | $490.7M FY2025 | -$25.5M | +110.5% | — |
| 43 | Cogent Biosciences, Inc. | COGT | $4.80B | $0 FY2025 | -$328.9M | — | — |
| 44 | Veradermics, Inc | MANE | $4.70B | $0 FY2025 | -$70.0M | — | — |
| 45 | Erasca, Inc. | ERAS | $4.60B | $0 FY2025 | -$124.5M | — | — |
| 46 | Indivior PLC | INDV | $4.39B | $1.24B FY2025 | $210.0M | +4.3% | 21.6 |
| 47 | Dianthus Therapeutics, Inc. | DNTH | $4.35B | $2.0M FY2025 | -$162.3M | -67.3% | — |
| 48 | Edgewise Therapeutics, Inc. | EWTX | $3.91B | $0 FY2025 | -$167.8M | — | — |
| 49 | AbCellera Biologics Inc. | ABCL | $3.85B | $75.1M FY2025 | -$146.4M | +160.6% | — |
| 50 | Organon & Co. | OGN | $3.72B | $6.22B FY2025 | $187.0M | -2.9% | 19.1 |
| 51 | Arcutis Biotherapeutics, Inc. | ARQT | $3.55B | $376.1M FY2025 | -$16.1M | +91.3% | — |
| 52 | Xenon Pharmaceuticals Inc. | XENE | $3.43B | $7.5M FY2025 | -$345.9M | — | — |
| 53 | Tango Therapeutics, Inc. | TNGX | $3.33B | $62.4M FY2025 | -$101.6M | +48.3% | — |
| 54 | Acadia Pharmaceuticals Inc | ACAD | $3.22B | $1.07B FY2025 | $391.0M | +11.9% | 8.1 |
| 55 | IDEAYA Biosciences, Inc. | IDYA | $3.15B | $218.7M FY2025 | -$113.7M | — | — |
| 56 | Viking Therapeutics, Inc. | VKTX | $3.10B | $0 FY2025 | -$359.6M | — | — |
| 57 | Precigen, Inc. | PGEN | $3.09B | $9.7M FY2025 | -$250.6M | +146.7% | — |
| 58 | Amylyx Pharmaceuticals, Inc. | AMLX | $2.99B | $0 FY2025 | -$144.7M | -100.0% | — |
| 59 | Arcus Biosciences, Inc. | RCUS | $2.84B | $247.0M FY2025 | -$353.0M | -4.3% | — |
| 60 | Liquidia Corp | LQDA | $2.72B | $158.3M FY2025 | -$68.9M | — | — |
| 61 | Enliven Therapeutics, Inc. | ELVN | $2.61B | $0 FY2025 | -$103.7M | — | — |
| 62 | Zai Lab Ltd | ZLAB | $2.58B | $460.2M FY2025 | -$175.5M | +15.3% | — |
| 63 | Nurix Therapeutics, Inc. | NRIX | $2.57B | $84.0M FY2025 | -$264.5M | +53.9% | — |
| 64 | NewAmsterdam Pharma Co N.V. | NAMS | $2.49B | $22.5M FY2025 | -$203.8M | -50.6% | — |
| 65 | Supernus Pharmaceuticals, Inc. | SUPN | $2.44B | $719.0M FY2025 | -$38.5M | +8.6% | — |
| 66 | SELLAS Life Sciences Group, Inc. | SLS | $2.35B | $0 FY2025 | -$26.9M | — | — |
| 67 | MBX Biosciences, Inc. | MBX | $2.34B | $0 FY2025 | -$87.0M | — | — |
| 68 | Prestige Consumer Healthcare Inc. | PBH | $2.31B | $1.09B FY2026 | $190.3M | -4.3% | 12.4 |
| 69 | Bausch Health Companies Inc. | BHC | $2.23B | $10.27B FY2025 | $157.0M | +6.7% | 14.0 |
| 70 | Disc Medicine, Inc. | IRON | $2.19B | $0 FY2025 | -$212.2M | — | — |
| 71 | Aurinia Pharmaceuticals Inc. | AUPH | $2.18B | $283.1M FY2025 | $287.2M | +20.4% | 7.9 |
| 72 | Harmony Biosciences Holdings, Inc. | HRMY | $2.18B | $868.5M FY2025 | $158.7M | +21.5% | 13.7 |
| 73 | PERRIGO Co plc | PRGO | $2.15B | $4.25B FY2025 | -$1.43B | -2.8% | — |
| 74 | Immunome Inc. | IMNM | $1.99B | $6.9M FY2025 | -$212.4M | -23.2% | — |
| 75 | Schrodinger, Inc. | SDGR | $1.96B | $255.9M FY2025 | -$103.3M | +23.3% | — |
| 76 | UroGen Pharma Ltd. | URGN | $1.93B | $109.8M FY2025 | -$153.5M | +21.4% | — |
| 77 | Trevi Therapeutics, Inc. | TRVI | $1.92B | $0 FY2025 | -$42.8M | — | — |
| 78 | Vera Therapeutics, Inc. | VERA | $1.92B | $0 FY2025 | -$299.6M | — | — |
| 79 | Palvella Therapeutics, Inc. | PVLA | $1.84B | $0 FY2025 | -$41.7M | — | — |
| 80 | Zymeworks Inc. | ZYME | $1.83B | $106.0M FY2025 | -$81.1M | +38.9% | — |
| 81 | Agios Pharmaceuticals, Inc. | AGIO | $1.80B | $54.0M FY2025 | -$412.8M | +48.0% | — |
| 82 | Xencor Inc | XNCR | $1.78B | $125.6M FY2025 | -$91.9M | +13.7% | — |
| 83 | Mineralys Therapeutics, Inc. | MLYS | $1.78B | $0 FY2025 | -$154.7M | — | — |
| 84 | Xeris Biopharma Holdings, Inc. | XERS | $1.76B | $291.8M FY2025 | $554,000 | +43.7% | — |
| 85 | Eton Pharmaceuticals, Inc. | ETON | $1.75B | $80.0M FY2025 | -$4.6M | +104.9% | — |
| 86 | Sarepta Therapeutics, Inc. | SRPT | $1.74B | $2.20B FY2025 | -$713.4M | +15.6% | — |
| 87 | Biohaven Ltd. | BHVN | $1.72B | $0 FY2025 | -$738.8M | — | — |
| 88 | Omeros Corp | OMER | $1.69B | $0 FY2025 | -$3.4M | — | — |
| 89 | Nuvation Bio Inc. | NUVB | $1.65B | $62.9M FY2025 | -$204.6M | +699.0% | — |
| 90 | Septerna, Inc. | SEPN | $1.64B | $46.0M FY2025 | -$48.9M | — | — |
| 91 | Ocular Therapeutix, Inc | OCUL | $1.63B | $52.0M FY2025 | -$265.9M | -18.5% | — |
| 92 | Structure Therapeutics Inc. | GPCR | $1.62B | $0 FY2025 | -$141.2M | — | — |
| 93 | Zenas BioPharma, Inc. | ZBIO | $1.59B | $10.0M FY2025 | -$377.7M | +100.0% | — |
| 94 | Ani Pharmaceuticals Inc | ANIP | $1.55B | $883.4M FY2025 | $78.3M | +43.8% | 21.3 |
| 95 | Innoviva, Inc. | INVA | $1.52B | $411.3M FY2025 | $271.2M | +14.7% | 6.3 |
| 96 | Ultragenyx Pharmaceutical Inc. | RARE | $1.52B | $673.0M FY2025 | -$575.0M | +20.1% | — |
| 97 | Phibro Animal Health Corp | PAHC | $1.51B | $1.52B FY2026 | $99.7M | +17.1% | 15.1 |
| 98 | COMPASS Pathways plc | CMPS | $1.50B | $0 FY2025 | -$287.9M | — | — |
| 99 | Stoke Therapeutics, Inc. | STOK | $1.49B | $184.4M FY2025 | -$6.9M | +404.5% | — |
| 100 | Pacira BioSciences, Inc. | PCRX | $1.46B | $726.4M FY2025 | $7.0M | +4.2% | 226.9 |
| 101 | uniQure N.V. | QURE | $1.41B | $16.1M FY2025 | -$199.0M | -40.6% | — |
| 102 | Rapport Therapeutics, Inc. | RAPP | $1.38B | $0 FY2025 | -$111.5M | — | — |
| 103 | Anaptysbio, Inc | ANAB | $1.31B | $234.6M FY2025 | -$13.2M | +157.0% | — |
| 104 | Nektar Therapeutics | NKTR | $1.25B | $55.2M FY2025 | -$164.1M | -43.9% | — |
| 105 | Syndax Pharmaceuticals Inc | SNDX | $1.24B | $172.4M FY2025 | -$285.4M | +627.8% | — |
| 106 | Tyra Biosciences, Inc. | TYRA | $1.22B | $0 FY2025 | -$119.9M | — | — |
| 107 | Oric Pharmaceuticals, Inc. | ORIC | $1.22B | $0 FY2025 | -$129.5M | — | — |
| 108 | Savara Inc | SVRA | $1.21B | $0 FY2025 | -$118.8M | — | — |
| 109 | Bicara Therapeutics Inc. | BCAX | $1.18B | $0 FY2025 | -$137.9M | — | — |
| 110 | Amphastar Pharmaceuticals, Inc. | AMPH | $1.15B | $719.9M FY2025 | $98.1M | -1.7% | 12.8 |
| 111 | Galecto, Inc. | GLTO | $1.13B | $0 FY2025 | -$209.8M | — | 4.7 |
| 112 | Janux Therapeutics, Inc. | JANX | $1.08B | $10.0M FY2025 | -$113.6M | -5.5% | — |
| 113 | Harrow, Inc. | HROW | $1.05B | $272.3M FY2025 | -$5.1M | +36.4% | — |
| 114 | LB Pharmaceuticals Inc | LBRX | $1.05B | $0 FY2025 | -$25.2M | — | — |
| 115 | Opko Health, Inc. | OPK | $997.0M | $606.9M FY2025 | -$225.7M | -14.9% | — |
| 116 | Maravai Lifesciences Holdings, Inc. | MRVI | $966.4M | $185.7M FY2025 | -$130.8M | -28.3% | — |
| 117 | Alto Neuroscience, Inc. | ANRO | $945.7M | $0 FY2025 | -$63.2M | — | — |
| 118 | Mannkind Corp | MNKD | $943.0M | $349.0M FY2025 | $5.9M | +22.2% | 152.5 |
| 119 | Rigel Pharmaceuticals Inc | RIGL | $922.5M | $294.3M FY2025 | $367.0M | +64.1% | 2.4 |
| 120 | Kura Oncology, Inc. | KURA | $873.4M | $67.5M FY2025 | -$278.7M | +25.2% | — |
| 121 | Corvus Pharmaceuticals, Inc. | CRVS | $869.2M | $0 FY2025 | -$15.3M | — | — |
| 122 | Cryoport, Inc. | CYRX | $855.0M | $176.2M FY2025 | $78.3M | -22.9% | 12.1 |
| 123 | Alumis Inc. | ALMS | $837.6M | $24.1M FY2025 | -$243.3M | — | — |
| 124 | Jade Biosciences, Inc. | JBIO | $819.3M | $0 FY2025 | -$127.4M | — | — |
| 125 | Arbutus Biopharma Corp | ABUS | $811.6M | $14.1M FY2025 | -$33.5M | +128.2% | — |
| 126 | Geron Corp | GERN | $804.8M | $183.6M FY2025 | -$83.5M | +140.1% | — |
| 127 | Climb Bio, Inc. | CLYM | $785.1M | $0 FY2025 | -$59.9M | — | — |
| 128 | Ardelyx, Inc. | ARDX | $774.0M | $407.3M FY2025 | -$61.6M | +22.1% | — |
| 129 | Annexon, Inc. | ANNX | $769.8M | $0 FY2025 | -$206.7M | — | — |
| 130 | MoonLake Immunotherapeutics | MLTX | $769.5M | $0 FY2025 | -$227.3M | — | — |
| 131 | ArriVent BioPharma, Inc. | AVBP | $766.0M | $0 FY2025 | -$166.3M | — | — |
| 132 | Verastem, Inc. | VSTM | $745.9M | $30.9M FY2025 | -$209.5M | +209.1% | — |
| 133 | Olema Pharmaceuticals, Inc. | OLMA | $733.3M | $0 FY2025 | -$162.5M | — | — |
| 134 | Shattuck Labs, Inc. | STTK | $712.5M | $1.0M FY2025 | -$48.8M | -82.5% | — |
| 135 | Lexicon Pharmaceuticals, Inc. | LXRX | $704.6M | $49.8M FY2025 | -$50.3M | +60.2% | — |
| 136 | Collegium Pharmaceutical, Inc | COLL | $698.9M | $780.6M FY2025 | $62.9M | +23.6% | 12.4 |
| 137 | CorMedix Inc. | CRMD | $683.4M | $311.7M FY2025 | $163.1M | +617.0% | 3.6 |
| 138 | Gyre Therapeutics, Inc. | GYRE | $675.3M | $116.6M FY2025 | $9.9M | +10.2% | 335.5 |
| 139 | Wave Life Sciences Ltd. | WVE | $640.6M | $42.7M FY2025 | -$204.4M | -60.6% | — |
| 140 | Zevra Therapeutics, Inc. | ZVRA | $637.3M | $106.5M FY2025 | $83.2M | +350.9% | 7.7 |
| 141 | Leap Therapeutics, Inc. | LPTX | $617.3M | $0 FY2025 | $4.8M | — | 40.6 |
| 142 | Monopar Therapeutics | MNPR | $615.7M | $0 FY2025 | -$13.7M | — | — |
| 143 | Design Therapeutics, Inc. | DSGN | $611.3M | $0 FY2025 | -$69.8M | — | — |
| 144 | Ironwood Pharmaceuticals Inc | IRWD | $600.2M | $296.2M FY2025 | $24.0M | -15.7% | 23.9 |
| 145 | Phathom Pharmaceuticals, Inc. | PHAT | $586.2M | $175.1M FY2025 | -$221.2M | +216.9% | — |
| 146 | Aquestive Therapeutics, Inc. | AQST | $583.7M | $44.5M FY2025 | -$83.8M | -22.6% | — |
| 147 | Immix Biopharma, Inc. | IMMX | $554.2M | $0 FY2025 | -$29.4M | — | — |
| 148 | Puma Biotechnology, Inc. | PBYI | $532.3M | $228.4M FY2025 | $31.1M | -0.9% | 16.6 |
| 149 | Avalo Therapeutics, Inc. | AVTX | $523.7M | $59,000 FY2025 | -$78.3M | -86.6% | — |
| 150 | CytomX Therapeutics, Inc. | CTMX | $509.0M | $76.2M FY2025 | -$17.4M | -44.8% | — |
| 151 | Aclaris Therapeutics, Inc. | ACRS | $495.3M | $7.8M FY2025 | -$64.9M | -58.2% | — |
| 152 | Evolus, Inc. | EOLS | $495.1M | $297.2M FY2025 | -$51.6M | +11.6% | — |
| 153 | Neurogene Inc. | NGNE | $486.2M | $0 FY2025 | -$90.4M | -100.0% | — |
| 154 | Rezolute, Inc. | RZLT | $479.0M | $0 FY2026 | -$77.6M | — | — |
| 155 | Opus Genetics, Inc. | IRD | $472.3M | $14.2M FY2025 | -$49.6M | +29.1% | — |
| 156 | Altimmune, Inc. | ALT | $450.6M | $41,000 FY2025 | -$88.1M | +105.0% | — |
| 157 | Arvinas, Inc. | ARVN | $449.4M | $262.6M FY2025 | -$80.8M | -0.3% | — |
| 158 | Prothena Corp Public LTD Co | PRTA | $435.9M | $9.7M FY2025 | -$244.1M | -92.8% | — |
| 159 | Ovid Therapeutics Inc. | OVID | $432.4M | $7.3M FY2025 | -$17.4M | — | — |
| 160 | Nuvectis Pharma, Inc. | NVCT | $426.1M | $0 FY2025 | -$26.4M | — | — |
| 161 | Sagimet Biosciences Inc. | SGMT | $423.9M | $0 FY2025 | -$51.0M | — | — |
| 162 | DiaMedica Therapeutics Inc. | DMAC | $421.5M | $0 FY2025 | -$32.8M | — | — |
| 163 | Silence Therapeutics plc | SLN | $419.0M | $559,000 FY2025 | -$88.6M | -98.7% | — |
| 164 | ARS Pharmaceuticals, Inc. | SPRY | $402.2M | $84.3M FY2025 | -$171.3M | -5.5% | — |
| 165 | Benitec Biopharma Inc. | BNTC | $401.8M | $0 FY2026 | -$45.5M | — | — |
| 166 | Atea Pharmaceuticals, Inc. | AVIR | $398.7M | $0 FY2025 | -$158.3M | — | — |
| 167 | Capricor Therapeutics, Inc. | CAPR | $398.5M | $0 FY2025 | -$105.0M | -100.0% | — |
| 168 | Assembly Biosciences, Inc. | ASMB | $383.5M | $72.3M FY2025 | -$6.1M | +153.5% | — |
| 169 | Relmada Therapeutics, Inc. | RLMD | $377.6M | $0 FY2025 | -$57.4M | — | — |
| 170 | MapLight Therapeutics, Inc. | MPLT | $357.8M | $0 FY2025 | -$161.2M | — | — |
| 171 | Emergent BioSolutions Inc. | EBS | $356.6M | $742.9M FY2025 | $52.6M | -28.8% | 7.4 |
| 172 | vTv Therapeutics Inc. | VTVT | $350.3M | $0 FY2025 | -$27.0M | -100.0% | — |
| 173 | Prelude Therapeutics Inc | PRLD | $350.3M | $12.1M FY2025 | -$99.5M | +73.4% | — |
| 174 | Arcturus Therapeutics Holdings Inc. | ARCT | $341.9M | $82.0M FY2025 | -$65.8M | -46.1% | — |
| 175 | Enanta Pharmaceuticals Inc | ENTA | $335.1M | $65.3M FY2025 | -$81.9M | -3.4% | — |
| 176 | Turn Therapeutics Inc. | TTRX | $315.8M | $0 FY2025 | -$3.2M | — | — |
| 177 | Contineum Therapeutics, Inc. | CTNM | $315.5M | $0 FY2025 | -$60.0M | — | — |
| 178 | Immunic, Inc. | IMUX | $292.9M | $0 FY2025 | -$97.2M | — | — |
| 179 | Fulcrum Therapeutics, Inc. | FULC | $280.7M | $0 FY2025 | -$74.9M | -100.0% | — |
| 180 | Indaptus Therapeutics, Inc. | INDP | $277.6M | $0 FY2025 | -$20.8M | — | — |
| 181 | Perspective Therapeutics, Inc. | CATX | $273.9M | $0 FY2025 | -$103.1M | — | — |
| 182 | Eledon Pharmaceuticals, Inc. | ELDN | $265.9M | $0 FY2025 | -$45.6M | — | — |
| 183 | ADC Therapeutics SA | ADCT | $263.5M | $81.4M FY2025 | -$142.6M | +14.8% | — |
| 184 | Rocket Pharmaceuticals, Inc. | RCKT | $263.4M | $0 FY2025 | -$223.1M | — | — |
| 185 | Vanda Pharmaceuticals Inc. | VNDA | $259.0M | $216.1M FY2025 | -$220.5M | +8.7% | — |
| 186 | Standard Biotools Inc. | LAB | $258.0M | $85.3M FY2025 | -$74.9M | -51.1% | — |
| 187 | Abeona Therapeutics Inc. | ABEO | $257.9M | $5.8M FY2025 | $71.2M | — | 4.5 |
| 188 | Bicycle Therapeutics PLC | BCYC | $253.4M | $72.6M FY2025 | -$219.0M | +105.8% | — |
| 189 | Whitehawk Therapeutics, Inc. | WHWK | $250.3M | $7.1M FY2025 | -$20.6M | -72.5% | — |
| 190 | BioAge Labs, Inc. | BIOA | $249.8M | $9.0M FY2025 | -$80.6M | — | — |
| 191 | Galectin Therapeutics Inc | GALT | $243.1M | $0 FY2025 | -$30.8M | — | — |
| 192 | Lifecore Biomedical, Inc. \de\ | LFCR | $241.2M | $128.9M FY2025 | -$38.7M | +0.5% | — |
| 193 | Amarin Corp Plcuk | AMRN | $241.1M | $213.6M FY2025 | -$38.8M | +4.4% | — |
| 194 | Helix Acquisition Corp. II | HLXB | $236.2M | $0 FY2025 | -$134.0M | — | — |
| 195 | Natures Sunshine Products Inc | NATR | $234.0M | $480.1M FY2025 | $19.5M | +5.7% | 12.0 |
| 196 | Immuneering Corp | IMRX | $230.3M | $0 FY2025 | -$56.0M | — | — |
| 197 | Greenwich LifeSciences, Inc. | GLSI | $226.6M | — FY2025 | -$19.4M | — | — |
| 198 | Keros Therapeutics, Inc. | KROS | $222.4M | $243.9M FY2025 | $87.0M | — | 4.9 |
| 199 | Siga Technologies Inc | SIGA | $221.4M | $94.6M FY2025 | $23.3M | -31.8% | 9.6 |
| 200 | Macrogenics Inc | MGNX | $217.5M | $149.5M FY2025 | -$74.6M | -0.3% | — |
| 201 | Evommune, Inc. | EVMN | $212.5M | $13.0M FY2025 | -$68.9M | — | — |
| 202 | Akebia Therapeutics, Inc. | AKBA | $207.6M | $236.2M FY2025 | -$5.3M | +47.5% | — |
| 203 | Entrada Therapeutics, Inc. | TRDA | $205.2M | $25.4M FY2025 | -$143.8M | -87.9% | — |
| 204 | Minerva Neurosciences, Inc. | NERV | $198.9M | $0 FY2025 | -$293.4M | — | — |
| 205 | Camp4 Therapeutics Corp | CAMP | $198.7M | $3.5M FY2025 | -$80.4M | +436.5% | — |
| 206 | Sionna Therapeutics, Inc. | SION | $197.8M | $0 FY2025 | -$75.3M | — | — |
| 207 | Cartesian Therapeutics, Inc. | RNAC | $196.2M | $2.8M FY2025 | -$130.3M | -92.8% | — |
| 208 | Upstream Bio, Inc. | UPB | $193.7M | $2.9M FY2025 | -$143.4M | +20.4% | — |
| 209 | Xilio Therapeutics, Inc. | XLO | $178.9M | $43.8M FY2025 | -$35.0M | +589.9% | — |
| 210 | Oramed Pharmaceuticals Inc. | ORMP | $177.2M | $2.0M FY2025 | $64.0M | — | 2.8 |
| 211 | Lyell Immunopharma, Inc. | LYEL | $175.5M | $36,000 FY2025 | -$274.4M | -41.0% | — |
| 212 | PepGen Inc. | PEPG | $173.0M | $0 FY2025 | -$89.7M | — | — |
| 213 | Zentalis Pharmaceuticals, Inc. | ZNTL | $171.2M | $0 FY2025 | -$137.1M | -100.0% | — |
| 214 | Q32 Bio Inc. | QTTB | $164.0M | $53.7M FY2025 | $29.8M | — | 3.3 |
| 215 | AN2 Therapeutics, Inc. | ANTX | $161.1M | $0 FY2025 | -$35.2M | — | — |
| 216 | Nkarta, Inc. | NKTX | $156.4M | $0 FY2025 | -$104.1M | — | — |
| 217 | Journey Medical Corp | DERM | $156.2M | $61.9M FY2025 | -$11.4M | +10.2% | — |
| 218 | Organogenesis Holdings Inc. | ORGO | $155.7M | $564.2M FY2025 | $37.0M | +17.0% | 8.1 |
| 219 | Korro Bio, Inc. | KRRO | $155.2M | $6.4M FY2025 | -$117.3M | +181.5% | — |
| 220 | Equillium, Inc. | EQ | $147.6M | $0 FY2025 | -$22.4M | -100.0% | — |
| 221 | Rani Therapeutics Holdings, Inc. | RANI | $137.2M | $1.6M FY2025 | -$29.7M | +58.9% | — |
| 222 | Alx Oncology Holdings Inc | ALXO | $132.9M | $0 FY2025 | -$101.7M | — | — |
| 223 | Foghorn Therapeutics Inc. | FHTX | $130.7M | $30.9M FY2025 | -$74.3M | +36.8% | — |
| 224 | Cue Biopharma, Inc. | CUE | $124.1M | $27.5M FY2025 | -$26.6M | +195.8% | — |
| 225 | Sensei Biotherapeutics, Inc. | SNSE | $121.4M | $0 FY2025 | -$21.1M | — | — |
| 226 | Pyxis Oncology, Inc. | PYXS | $118.4M | $13.9M FY2025 | -$79.6M | -14.2% | — |
| 227 | OnKure Therapeutics, Inc. | OKUR | $116.9M | $0 FY2025 | -$59.5M | — | — |
| 228 | TuHURA Biosciences, Inc. | HURA | $115.8M | $0 FY2025 | -$30.1M | — | — |
| 229 | GENELUX Corp | GNLX | $113.3M | $8,000 FY2025 | -$32.1M | +0.0% | — |
| 230 | Cumberland Pharmaceuticals Inc | CPIX | $107.4M | $44.5M FY2025 | -$2.8M | +17.6% | — |
| 231 | Coya Therapeutics, Inc. | COYA | $105.0M | $7.9M FY2025 | -$21.2M | +123.6% | — |
| 232 | Tonix Pharmaceuticals Holding Corp. | TNXP | $102.0M | $13.1M FY2025 | -$124.0M | +29.8% | — |
| 233 | NRX Pharmaceuticals, Inc. | NRXP | $101.7M | $1.2M FY2025 | -$28.6M | — | — |
| 234 | Unicycive Therapeutics, Inc. | UNCY | $100.4M | $0 FY2025 | -$26.6M | — | — |
| 235 | Spruce Biosciences, Inc. | SPRB | $98.1M | $0 FY2025 | -$39.0M | -100.0% | — |
| 236 | Rallybio Corp | RLYB | $96.9M | $858,000 FY2025 | -$9.0M | +43.0% | — |
| 237 | Polaryx Therapeutics, Inc. | PLYX | $93.7M | $0 FY2025 | -$9.0M | — | — |
| 238 | Corbus Pharmaceuticals Holdings, Inc. | CRBP | $92.8M | $0 FY2025 | -$78.5M | — | — |
| 239 | Anixa Biosciences Inc | ANIX | $91.3M | — FY2025 | -$10.9M | — | — |
| 240 | Biomea Fusion, Inc. | BMEA | $91.2M | $0 FY2025 | -$61.8M | — | — |
| 241 | PDS Biotechnology Corp | PDSB | $89.1M | $0 FY2025 | -$34.5M | — | — |
| 242 | Aardvark Therapeutics, Inc. | AARD | $88.3M | $0 FY2025 | -$57.6M | — | — |
| 243 | Citius Oncology, Inc. | CTOR | $85.4M | — FY2025 | -$24.8M | — | — |
| 244 | Inovio Pharmaceuticals, Inc. | INO | $81.6M | $65,343 FY2025 | -$84.9M | -70.0% | — |
| 245 | Tenax Therapeutics, Inc. | TENX | $81.4M | $0 FY2025 | -$52.6M | — | — |
| 246 | iBio, Inc. | IBIO | $81.2M | $100,000 FY2026 | -$33.0M | -75.0% | — |
| 247 | Talphera, Inc. | TLPH | $80.8M | $28,000 FY2025 | -$14.3M | — | — |
| 248 | ProMIS Neurosciences Inc. | PMN | $79.2M | $0 FY2025 | -$39.7M | — | — |
| 249 | Rafael Holdings, Inc. | RFL | $76.3M | $917,000 FY2025 | -$30.5M | +44.0% | — |
| 250 | Verrica Pharmaceuticals Inc. | VRCA | $76.3M | $35.6M FY2025 | -$17.9M | +370.2% | — |
| 251 | Lifevantage Corp | LFVN | $75.6M | $182.6M FY2026 | $5.1M | -20.1% | 14.9 |
| 252 | Heron Therapeutics, Inc. | HRTX | $74.2M | $154.9M FY2025 | -$20.2M | +7.4% | — |
| 253 | Medicinova Inc | MNOV | $73.8M | $409,657 FY2025 | -$12.0M | — | — |
| 254 | Acrivon Therapeutics, Inc. | ACRV | $73.2M | $0 FY2025 | -$77.9M | — | — |
| 255 | PMV Pharmaceuticals, Inc. | PMVP | $72.1M | $0 FY2025 | -$77.7M | — | — |
| 256 | MAIA Biotechnology, Inc. | MAIA | $70.5M | $0 FY2025 | -$22.4M | — | — |
| 257 | Spero Therapeutics, Inc. | SPRO | $66.7M | $66.8M FY2025 | $8.6M | +39.2% | 7.7 |
| 258 | Telomir Pharmaceuticals, Inc. | TELO | $66.3M | — FY2025 | -$10.4M | — | — |
| 259 | XBiotech Inc. | XBIT | $65.9M | $0 FY2025 | -$45.5M | — | — |
| 260 | Neonc Technologies Holdings, Inc. | NTHI | $64.0M | $39,990 FY2025 | -$62.1M | — | — |
| 261 | OS Therapies Inc | OSTX | $63.7M | $0 FY2025 | -$28.8M | — | — |
| 262 | Cingulate Inc. | CING | $62.2M | $0 FY2025 | -$22.4M | — | — |
| 263 | Fortress Biotech, Inc. | FBIO | $62.0M | $63.3M FY2025 | $6.8M | +9.7% | — |
| 264 | Gain Therapeutics, Inc. | GANX | $60.5M | $0 FY2025 | -$20.2M | — | — |
| 265 | Pliant Therapeutics, Inc. | PLRX | $59.9M | $0 FY2025 | -$149.3M | — | — |
| 266 | Oncolytics Biotech Inc | ONCY | $58.7M | $0 FY2025 | -$28.8M | — | — |
| 267 | Connect Biopharma Holdings Ltd | CNTB | $57.8M | $64,000 FY2025 | -$55.5M | -99.8% | — |
| 268 | Lixte Biotechnology Holdings, Inc. | LIXT | $57.7M | — FY2025 | -$6.1M | — | — |
| 269 | Adicet Bio, Inc. | ACET | $54.9M | $0 FY2025 | -$116.8M | — | — |
| 270 | Boundless Bio, Inc. | BOLD | $54.6M | $0 FY2025 | -$58.2M | — | — |
| 271 | Aldeyra Therapeutics, Inc. | ALDX | $54.3M | $0 FY2025 | -$33.8M | — | — |
| 272 | Mereo BioPharma Group plc | MREO | $51.4M | $500,000 FY2025 | -$41.9M | — | — |
| 273 | Rein Therapeutics, Inc. | RNTX | $50.6M | $0 FY2025 | -$49.9M | — | — |
| 274 | Veru Inc. | VERU | $50.5M | $0 FY2025 | -$22.7M | -100.0% | — |
| 275 | Werewolf Therapeutics, Inc. | HOWL | $48.2M | $0 FY2025 | -$60.8M | — | — |
| 276 | Scynexis Inc | SCYX | $47.2M | $20.6M FY2025 | -$8.6M | +450.0% | — |
| 277 | Dogwood Therapeutics, Inc. | DWTX | $44.4M | $0 FY2025 | -$34.3M | — | — |
| 278 | Celularity Inc | CELU | $43.0M | $26.6M FY2025 | -$91.7M | -51.0% | — |
| 279 | Clene Inc. | CLNN | $42.0M | $200,000 FY2025 | -$26.2M | -41.5% | — |
| 280 | MEI Pharma, Inc. | MEIP | $41.8M | $267,000 FY2026 | -$71.2M | -99.6% | — |
| 281 | Gossamer Bio, Inc. | GOSS | $40.1M | $48.5M FY2025 | -$170.4M | -57.7% | — |
| 282 | Annovis Bio, Inc. | ANVS | $39.8M | $0 FY2025 | -$28.9M | — | — |
| 283 | CNS Pharmaceuticals, Inc. | CNSP | $36.6M | $0 FY2025 | -$15.9M | — | — |
| 284 | Cassava Sciences Inc | SAVA | $35.7M | $0 FY2025 | -$91.0M | — | — |
| 285 | Grace Therapeutics, Inc. | GRCE | $34.4M | $0 FY2026 | -$7.8M | — | — |
| 286 | Elicio Therapeutics, Inc. | ELTX | $34.1M | $0 FY2025 | -$39.6M | — | — |
| 287 | Incannex Healthcare Inc. | IXHL | $33.9M | $0 FY2026 | -$19.3M | -100.0% | — |
| 288 | Impact Biomedical Inc. | IBO | $33.9M | $32,000 FY2025 | -$11.8M | — | — |
| 289 | NextCure, Inc. | NXTC | $33.3M | $0 FY2025 | -$55.8M | — | — |
| 290 | Aprea Therapeutics, Inc. | APRE | $32.1M | $0 FY2025 | -$12.6M | — | — |
| 291 | Actinium Pharmaceuticals, Inc. | ATNM | $31.4M | $90,000 FY2025 | -$33.9M | — | — |
| 292 | Rockwell Medical, Inc. | RMTI | $31.1M | $69.3M FY2025 | -$5.3M | -31.8% | — |
| 293 | China Pharma Holdings, Inc. | CPHI | $30.4M | $4.1M FY2025 | -$3.2M | -8.5% | — |
| 294 | Serina Therapeutics, Inc. | SER | $29.8M | $130,000 FY2025 | -$19.2M | +132.1% | — |
| 295 | Mira Pharmaceuticals, Inc. | MIRA | $28.0M | — FY2025 | -$10.4M | — | — |
| 296 | IGC Pharma, Inc. | IGC | $27.1M | $1.3M FY2025 | -$7.1M | -5.5% | — |
| 297 | BriaCell Therapeutics Corp. | BCTX | $26.9M | $0 FY2025 | -$26.3M | — | — |
| 298 | Nanoviricides, Inc. | NNVC | $26.6M | $0 FY2026 | -$8.2M | — | — |
| 299 | Context Therapeutics Inc. | CNTX | $26.2M | $0 FY2025 | -$36.1M | — | — |
| 300 | Edesa Biotech, Inc. | EDSA | $25.7M | $0 FY2025 | -$7.2M | — | — |
| 301 | Abvc Biopharma, Inc. | ABVC | $25.5M | — FY2025 | -$7.9M | — | — |
| 302 | BeyondSpring Inc. | BYSI | $25.0M | $0 FY2025 | -$1.0M | — | — |
| 303 | Seres Therapeutics, Inc. | MCRB | $24.7M | $789,000 FY2025 | $5.7M | — | 4.0 |
| 304 | Aytu Biopharma, Inc | AYTU | $24.5M | $57.6M FY2026 | -$14.3M | -13.3% | — |
| 305 | Fibrogen Inc | FGEN | $23.8M | $6.4M FY2025 | $183.5M | -78.3% | 0.1 |
| 306 | CervoMed Inc. | CRVO | $23.3M | $4.0M FY2025 | -$27.0M | -58.9% | — |
| 307 | Palatin Technologies Inc | PTNT | $23.2M | $7.5M FY2026 | -$8.4M | — | — |
| 308 | TherapeuticsMD, Inc. | TXMD | $22.8M | $3.0M FY2025 | -$569,000 | +71.6% | — |
| 309 | Atossa Therapeutics, Inc. | ATOS | $22.8M | $0 FY2025 | -$34.8M | — | — |
| 310 | Mainz Biomed N.V. | MYNZ | $20.0M | $537,080 FY2025 | -$16.2M | — | — |
| 311 | Cyclerion Therapeutics, Inc. | CYCN | $19.2M | $2.1M FY2025 | -$3.5M | +3.7% | — |
| 312 | Marker Therapeutics, Inc. | MRKR | $17.8M | $3.5M FY2025 | -$12.2M | -46.2% | — |
| 313 | Cellectar Biosciences, Inc. | CLRB | $17.0M | $0 FY2025 | -$21.8M | — | — |
| 314 | VYNE Therapeutics Inc. | VYNE | $16.0M | $570,000 FY2025 | -$26.5M | +13.8% | — |
| 315 | Kiora Pharmaceuticals Inc | KPRX | $15.3M | $0 FY2025 | -$10.8M | -100.0% | — |
| 316 | Adial Pharmaceuticals, Inc. | ADIL | $15.2M | $0 FY2025 | -$8.0M | — | — |
| 317 | Neuphoria Therapeutics Inc. | NEUP | $14.9M | $1.2M FY2026 | -$13.5M | -92.5% | — |
| 318 | Cocrystal Pharma, Inc. | COCP | $14.9M | $0 FY2025 | -$8.8M | — | — |
| 319 | Akari Therapeutics Plc | AKTX | $14.2M | $0 FY2025 | -$17.3M | — | — |
| 320 | Allarity Therapeutics, Inc. | ALLR | $13.8M | $320,000 FY2025 | -$11.2M | — | — |
| 321 | ReShape Lifesciences Inc. | RSLS | $13.8M | $319,714 FY2025 | -$10.3M | -96.0% | — |
| 322 | Pasithea Therapeutics Corp. | KTTA | $13.6M | $0 FY2025 | -$20.4M | — | — |
| 323 | Lipocine Inc. | LPCN | $13.3M | $2.0M FY2025 | -$9.6M | -82.3% | — |
| 324 | Citius Pharmaceuticals, Inc. | CTXR | $12.5M | — FY2025 | -$37.4M | — | — |
| 325 | Karyopharm Therapeutics Inc. | KPTI | $12.4M | $146.1M FY2025 | -$196.0M | +0.6% | — |
| 326 | Quoin Pharmaceuticals, Ltd. | QNRX | $11.8M | $0 FY2025 | -$15.8M | — | — |
| 327 | Hoth Therapeutics, Inc. | HOTH | $11.7M | — FY2025 | -$12.5M | — | — |
| 328 | AEON Biopharma, Inc. | AEON | $11.6M | $0 FY2025 | -$39.2M | — | — |
| 329 | Biofrontera Inc. | BFRI | $11.5M | $41.7M FY2025 | -$10.5M | +11.8% | — |
| 330 | Dare Bioscience, Inc. | DARE | $11.1M | $1.0M FY2025 | -$13.4M | — | — |
| 331 | Actuate Therapeutics, Inc. | ACTU | $11.1M | $0 FY2025 | -$22.2M | — | — |
| 332 | Phio Pharmaceuticals Corp. | PHIO | $10.9M | $0 FY2025 | -$8.7M | — | — |
| 333 | BullFrog AI Holdings, Inc. | BFRG | $10.7M | $116,670 FY2025 | -$6.5M | — | — |
| 334 | Tempest Therapeutics, Inc. | TPST | $10.4M | $0 FY2025 | -$26.3M | — | — |
| 335 | Theriva Biologics, Inc. | TOVX | $10.1M | $0 FY2025 | -$23.7M | — | — |
| 336 | GT Biopharma, Inc. | GTBP | $10.1M | — FY2025 | -$28.4M | — | — |
| 337 | Lisata Therapeutics, Inc. | LSTA | $9.8M | $170,000 FY2025 | -$16.6M | -83.0% | — |
| 338 | Tvardi Therapeutics, Inc. | TVRD | $9.8M | $0 FY2025 | -$18.2M | -100.0% | — |
| 339 | Vistagen Therapeutics, Inc. | VTGN | $9.0M | $1.3M FY2026 | -$69.7M | +161.1% | — |
| 340 | Lantern Pharma Inc. | LTRN | $8.8M | $0 FY2025 | -$17.1M | — | — |
| 341 | Biovie Inc. | BIVI | $8.7M | $0 FY2026 | -$22.1M | — | — |
| 342 | Aspire Biopharma Holdings, Inc. | ASBP | $8.5M | $6,202 FY2025 | -$24.5M | — | — |
| 343 | MetaVia Inc. | MTVA | $8.5M | $0 FY2025 | -$13.0M | — | — |
| 344 | Apimeds Pharmaceuticals US, Inc. | APUS | $7.9M | — FY2025 | -$6.0M | — | — |
| 345 | Skye Bioscience, Inc. | SKYE | $7.6M | $0 FY2025 | -$55.9M | — | — |
| 346 | Ensysce Biosciences, Inc. | ENSC | $7.5M | $5.1M FY2025 | -$10.2M | -2.8% | — |
| 347 | Alaunos Therapeutics, Inc. | TCRT | $7.4M | $5,000 FY2025 | -$4.2M | -50.0% | — |
| 348 | Exicure, Inc. | XCUR | $7.3M | $0 FY2025 | -$4.9M | -100.0% | — |
| 349 | Bolt Biotherapeutics, Inc. | BOLT | $7.2M | $7.7M FY2025 | -$33.4M | +0.1% | — |
| 350 | Curanex Pharmaceuticals Inc | CURX | $6.9M | $0 FY2025 | -$4.2M | — | — |
| 351 | Longeveron Inc. | LGVN | $6.7M | $1.2M FY2025 | -$22.7M | -49.9% | — |
| 352 | Traws Pharma, Inc. | TRAW | $6.5M | $2.8M FY2025 | $9.2M | — | 0.5 |
| 353 | Alzamend Neuro, Inc. | ALZN | $6.0M | $0 FY2026 | -$8.8M | — | — |
| 354 | FibroBiologics, Inc. | FBLG | $6.0M | $0 FY2025 | -$18.6M | — | — |
| 355 | Imunon, Inc. | IMNN | $5.6M | $0 FY2025 | -$14.5M | — | — |
| 356 | Enveric Biosciences, Inc. | ENVB | $5.6M | $0 FY2025 | -$8.8M | — | — |
| 357 | InMed Pharmaceuticals Inc. | INM | $5.5M | $0 FY2026 | -$12.6M | -100.0% | — |
| 358 | Soligenix, Inc. | SNGX | $5.3M | $0 FY2025 | -$11.1M | -100.0% | — |
| 359 | Shuttle Pharmaceuticals Holdings, Inc. | SHPH | $5.3M | — FY2025 | -$11.7M | — | — |
| 360 | Scienture Holdings, Inc. | SCNX | $5.1M | $431,609 FY2025 | -$41.5M | +215.9% | — |
| 361 | Acurx Pharmaceuticals, Inc. | ACXP | $5.1M | $0 FY2025 | -$8.0M | — | — |
| 362 | Pulmatrix, Inc. | PULM | $5.0M | — FY2025 | -$5.2M | — | — |
| 363 | Processa Pharmaceuticals, Inc. | PCSA | $4.9M | $0 FY2025 | -$13.6M | — | — |
| 364 | Xenetic Biosciences, Inc. | XBIO | $4.8M | $3.0M FY2025 | -$2.7M | +19.0% | — |
| 365 | Lexaria Bioscience Corp. | LEXX | $4.6M | $705,923 FY2025 | -$11.9M | +52.0% | — |
| 366 | CalciMedica, Inc. | CALC | $3.8M | $713,000 FY2025 | -$29.6M | — | — |
| 367 | Medicus Pharma Ltd. | MDCX | $3.6M | $0 FY2025 | -$47.3M | — | — |
| 368 | Renovaro Inc. | RENB | $3.5M | $51,992 FY2026 | -$3.6M | — | — |
| 369 | Dermata Therapeutics, Inc. | DRMA | $3.5M | $0 FY2025 | -$7.6M | — | — |
| 370 | Cadrenal Therapeutics, Inc. | CVKD | $2.9M | $0 FY2025 | -$13.2M | — | — |
| 371 | GRI Bio, Inc. | GRI | $2.8M | $0 FY2025 | -$12.0M | — | — |
| 372 | Revelation Biosciences, Inc. | REVB | $2.8M | $0 FY2025 | -$8.9M | — | — |
| 373 | Ernexa Therapeutics Inc. | ERNA | $2.6M | — FY2025 | -$14.1M | — | — |
| 374 | Mustang Bio, Inc. | MBIO | $2.5M | $0 FY2025 | -$1.9M | — | — |
| 375 | Kairos Pharma, LTD. | KAPA | $2.5M | — FY2025 | -$5.4M | — | — |
| 376 | Moleculin Biotech, Inc. | MBRX | $2.5M | $0 FY2025 | -$33.6M | — | — |
| 377 | 60 Degrees Pharmaceuticals, Inc. | SXTP | $2.4M | $1.0M FY2025 | -$7.4M | +65.5% | — |
| 378 | Aptevo Therapeutics Inc. | APVO | $2.1M | $0 FY2025 | -$26.0M | — | — |
| 379 | Oragenics Inc | OGEN | $2.0M | $0 FY2025 | -$9.8M | — | — |
| 380 | Jupiter Neurosciences, Inc. | JUNS | $1.9M | $21,796 FY2025 | -$8.6M | — | — |
| 381 | HCW Biologics Inc. | HCWB | $1.7M | $54,232 FY2025 | -$8.0M | -97.9% | — |
| 382 | Transcode Therapeutics, Inc. | RNAZ | $1.6M | $0 FY2025 | -$34.7M | — | — |
| 383 | PMGC Holdings Inc. | ELAB | $1.4M | $590,084 FY2025 | -$7.7M | — | — |
| 384 | Azitra, Inc. | AZTR | $1.4M | $0 FY2025 | -$11.0M | -100.0% | — |
| 385 | Silo Pharma, Inc. | SILO | $1.3M | $72,102 FY2025 | -$4.2M | +0.0% | — |
| 386 | Onconetix, Inc. | ONCO | $1.2M | $815,371 FY2025 | -$14.0M | -67.7% | — |
| 387 | GeoVax Labs, Inc. | GOVX | $1.2M | $2.5M FY2025 | -$21.5M | -37.1% | — |
| 388 | Genprex, Inc. | GNPX | $1.2M | $0 FY2025 | -$16.2M | — | — |
| 389 | Larimar Therapeutics, Inc. | LRMR | $1.1M | $0 FY2025 | -$165.7M | — | — |
| 390 | Matinas BioPharma Holdings, Inc. | MTNB | $1.1M | $0 FY2025 | -$10.3M | — | — |
| 391 | Artelo Biosciences, Inc. | ARTL | $897,973 | $0 FY2025 | -$12.9M | — | — |
| 392 | Salarius Pharmaceuticals, Inc. | SLRX | $659,640 | $0 FY2025 | -$12.5M | — | — |
| 393 | N2OFF, Inc. | NITO | $574,560 | $0 FY2025 | -$4.0M | -100.0% | — |
| 394 | Propanc Biopharma, Inc. | PPCB | $463,530 | — FY2026 | -$18.9M | — | — |
| 395 | Sunshine Biopharma Inc. | SBFM | $322,216 | $36.3M FY2025 | -$6.0M | +4.1% | — |
| 396 | Jaguar Health, Inc. | JAGX | $224,396 | $11.5M FY2025 | -$53.6M | -1.5% | — |
| 397 | Tivic Health Systems, Inc. | TIVC | $209,560 | $0 FY2025 | -$8.9M | -100.0% | — |
| 398 | KALA BIO, Inc. | KALA | $19,281 | $0 FY2025 | -$27.0M | — | — |
| 399 | Conduit Pharmaceuticals Inc. | CDT | $9,594 | $0 FY2025 | -$39.2M | — | — |
| 400 | Viridian Therapeutics, Inc.\DE | VRDN | — | $70.8M FY2025 | -$342.6M | — | — |
| 401 | Dyne Therapeutics, Inc. | DYN | — | $0 FY2025 | -$446.2M | — | — |
| 402 | Milestone Pharmaceuticals Inc. | MIST | — | $0 FY2025 | -$63.1M | — | — |
| 403 | Crescent Biopharma, Inc. | CBIO | — | $10.8M FY2025 | -$153.9M | — | — |
Market cap and P/E use the latest closing price; revenue and net income are from each company's most recent annual report (10-K) filed with the SEC. Click a company for its full financial statements.